Hyderabad: ThromboGenics NV, a biotechnology company focused on vascular disease, has completed a licence agreement with city-based Bharat Biotech International for manufacturing, clinical development of THR-100, a novel variant of Recombinant Staphylokinase, in developing countries and certain industrialised countries. THR-100 is a thrombolytic agent developed for treatment of acute myocardial infarction (AMI or heart attack) and other vascular diseases based on its ability to dissolve blood clots.